NEW YORK, Aug. 3, 2017 /PRNewswire/ -- The nationwide law firm of Bernstein Liebhard LLP is evaluating potential Actemra lawsuit filings on behalf of individuals who suffered serious complications allegedly related to its use, including heart attacks, heart failure, stroke, lung disease, and death. The evaluations are being offered in the wake of a STAT investigation that linked the novel Rheumatoid Arthritis (RA) drug to hundreds of deaths and other complications that are not currently listed on the Actemra label.
"The STAT investigation was disturbing. Actemra patients who experienced serious side effects as detailed in the report could be entitled to damages from the manufacturers of this medication," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices.
Actemra FDA Adverse Event Reports
Actemra (tocilizumab) was approved by the U.S. Food & Drug Administration (FDA) in 2010. In addition to RA, its approved indications now include Polyarticular Juvenile Idiopathic Arthritis (PJIA), Systemic Juvenile Idiopathic Arthritis (SJIA) and Giant Cell Arteritis (GCA). Actemra can be administered as a monthly intravenous infusion, or as a weekly/biweekly subcutaneous injection.
Prior to its approval, FDA reviewers expressed concern about clinical data that suggested Actemra could increase blood lipid levels, potentially resulting in an elevated risk of heart attacks and other cardiovascular events. The FDA cleared Actemra on the condition that Roche AG conduct long-term studies of its potential side effects.
Published in June 2017, the STAT investigation reviewed more than 500,000 FDA adverse event reports related to various RA medications. The review uncovered more than 13,000 incidents associated with Actemra, including cases of:
- Interstitial lung disease
- Heart attack
- Heart failure
While the labels for other RA medications do note some of these risks, Actemra's labeling does not. Yet STAT's review "found clear evidence" that the potential for many of these complications, such as heart attack or stroke, "were as high or higher for Actemra patients than for patients taking some competing drugs."
Actemra patients who experienced any of the unlabeled side effects detailed by STAT may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. For more details on filing an Actemra lawsuit and to obtain a free, no-obligation legal review, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
View original content:http://www.prnewswire.com/news-releases/actemra-lawsuit-evaluations-offered-by-bernstein-liebhard-llp-following-report-linking-novel-ra-medication-to-serious-unlabeled-side-effects-including-heart-attacks-heart-failure-stroke-lung-disease-pancreatitis-and-death-300499230.html
SOURCE Bernstein Liebhard LLP